Other equities research analysts have also issued reports about the stock. JPMorgan Chase & Co. restated a neutral rating on shares of Qiagen in a research report on Tuesday, November 7th. Evercore ISI assumed coverage on shares of Qiagen in a research report on Wednesday, January 3rd. They set an outperform rating and a $35.00 target price on the stock. BidaskClub upgraded shares of Qiagen from a sell rating to a hold rating in a research report on Wednesday, December 20th. Zacks Investment Research lowered shares of Qiagen from a hold rating to a sell rating in a research report on Thursday, November 9th. Finally, Cowen reiterated a hold rating and issued a $34.00 price objective on shares of Qiagen in a research report on Thursday, December 21st. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the stock. Qiagen has an average rating of Hold and an average target price of $34.63.
Shares of Qiagen (NASDAQ QGEN) traded up $0.31 during midday trading on Friday, hitting $32.87. 1,831,029 shares of the company’s stock traded hands, compared to its average volume of 1,010,000. The stock has a market cap of $7,520.00, a price-to-earnings ratio of 84.28, a P/E/G ratio of 1.81 and a beta of 1.10. Qiagen has a 52 week low of $27.51 and a 52 week high of $36.34. The company has a quick ratio of 4.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.68.
Institutional investors have recently added to or reduced their stakes in the stock. Fox Run Management L.L.C. purchased a new stake in shares of Qiagen in the 3rd quarter worth about $753,000. OxFORD Asset Management LLP boosted its position in shares of Qiagen by 6.7% in the 3rd quarter. OxFORD Asset Management LLP now owns 81,216 shares of the company’s stock worth $2,558,000 after buying an additional 5,116 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of Qiagen in the 3rd quarter worth about $10,110,000. AXA boosted its position in shares of Qiagen by 5.0% in the 3rd quarter. AXA now owns 405,798 shares of the company’s stock worth $12,783,000 after buying an additional 19,268 shares in the last quarter. Finally, Cubist Systematic Strategies LLC boosted its position in shares of Qiagen by 27.7% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 16,208 shares of the company’s stock worth $543,000 after buying an additional 3,519 shares in the last quarter. Institutional investors and hedge funds own 61.39% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Qiagen’s (QGEN) Buy Rating Reaffirmed at Commerzbank” was posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3148028/qiagens-qgen-buy-rating-reaffirmed-at-commerzbank.html.
Qiagen Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.